Pfizer (NYSE:PFE) has entered into a collaborative research agreement with Atavistik Bio for the discovery of novel precision ...

Collaboration will leverage Atavistik Bio’s proprietary AMPS™ platform to rapidly identify and validate novel allosteric binders against two ...

Our work encompasses a broad range of molecular mechanisms of action, spanning covalent inhibitors, allosteric inhibitors, enzyme activators, protein (or protein complex) stabilizers, and protein ...

INR:1941. lv bets Agios' innovative allosteric activator reaches Phase 3 clinical endpoint and is expected to submit regulatory application in the second quarter Janssen' ...

Atavistik Bio Inc. has entered into a research collaboration with Pfizer Inc. to accelerate the discovery of novel precision allosteric therapeutics for unmet medical needs. Under the collaboration, ...